1. Carter HB, partin AW. Diagnosis and staging of prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA editors. Campbell-Walsh Urology. 8th ed. Sydney: Elsevier Health Sciences; 2002.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.
3. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17(4):337–47.
4. Glovamucci EP. Nutritional and environmental epidemiology of prostate cancer. In: Carrol P, amico AV editors. prostate cancer principles and practice. 15th ed. Philadelphia: wolters kluwer company; 2002.
5. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, et al. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. World J Urol. 2007;25(1):95–103.
6. Olsen SH, Walzak J. Prostate cancer: rate and risk. Atlantic cancer genetics network. 2002;68(4):36–8.
7. Tulloch-Reid MK, Aiken WD, Morrison BF, Tulloch T, Mayhew R, Wan RL, et al. Body mass index and prostate specific antigen levels in Jamaican men. West Indian Med J. 2011;60(3):316–21.
8. Cox AK, Holliday RE, Gregory PS, Joseph WA, Fei D. The effects of body mass index on pretreatment characteristics, treatment choice, and response to treatment of intermediate- and highgrade prostate cancer. J Clin Oncol. 2012;30(5).
9. Lujan M, Paez A, Llanes L, Miravalles E, Berenguer A. Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis. 2001;4(3):146–9.
10. Ayatollahi SM, Khezri AA, Shirazi M, Lotfi M, Askarian M, Ariafar A, et al. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol. 2009;6(1):40–8.
11. Pater LE, Hart KW, Blonigen BJ, Lindsell CJ, Barrett WL. Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population. Am J Clin Oncol. 2012;35(5):490–2